Sridhar K. Rabindran

10.6k citations

45 papers · 5.7k indexed · 2 hit papers · h-index 29

Molecular Biology top 2%
Oncology top 1%
Pulmonary and Respiratory Medicine top 2%
Organic Chemistry top 2%
Cancer Research top 5%

Co-authors: Carl Wu Joachim Clos Lee M. Greenberger Jan Wiśniewski Allan Wissner Gianfranco Giorgi Chi Wu John P. McGinnis
Topics: Heat shock proteins research (10 papers)Cancer-related Molecular Pathways (8 papers)HER2/EGFR in Cancer Research (6 papers)
Cited by: Aging Oncology Physical and Theoretical Chemistry
Journals: Nature Science Cell
Partner nations: United States Canada Germany

In The Last Decade

Sridhar K. Rabindran

44 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

2005 774 citations Eunice L. Kwak, Raffaella Sordella et al. Proceedings of the National Academy of Sciences profile →
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

2004 503 citations Sridhar K. Rabindran, Carolyn Discafani et al. Cancer Research profile →

Peers

Countries citing papers authored by Sridhar K. Rabindran

Since Specialization

Citations

This map shows the geographic impact of Sridhar K. Rabindran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sridhar K. Rabindran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sridhar K. Rabindran more than expected).

Fields of papers citing papers by Sridhar K. Rabindran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sridhar K. Rabindran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sridhar K. Rabindran. The network helps show where Sridhar K. Rabindran may publish in the future.

Co-authorship network of co-authors of Sridhar K. Rabindran

This figure shows the co-authorship network connecting the top 25 collaborators of Sridhar K. Rabindran. A scholar is included among the top collaborators of Sridhar K. Rabindran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sridhar K. Rabindran. Sridhar K. Rabindran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	127TiP: RELATIVITY-1093: A randomized, phase III study of first-line nivolumab (NIVO) + relatlimab (RELA) high dose (HD) with platinum-doublet chemotherapy (PDCT) vs pembrolizumab (PEMBRO) + PDCT in patients with metastatic NSCLC having tumor PD-L1 expression ≥ 1% and non-squamous (NSQ) histology 2025 ·Journal of Thoracic Oncology ·(unknown),N. Girard,Hidetoshi Hayashi,(unknown),(unknown),(unknown),(unknown),Yi‐Long Wu,(unknown),Muhammad Asif Qureshi,Dirk Kessler,Sridhar K. Rabindran,Palanikumar Ravindran,(unknown)	0
2	Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial 2023 ·ESMO Open ·Hossein Borghaei,Kenneth J. O’Byrne,Luis Paz‐Ares,T-E. Ciuleanu,(unknown),Adam Płużański,Adnan Nagrial,Libor Havel,Rubén Dario Kowalyszyn,Clarisse Audigier-Valette,Julie R. Brahmer,Martin Reck,(unknown),Li Zhang,(unknown),Sridhar K. Rabindran,Faith E. Nathan,David Balli,Yi‐Long Wu	23
3	GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers 2009 ·Molecular Cancer Therapeutics ·Peter Sabbatini,Susan Korenchuk,Jason L. Rowand,Arthur Groy,Qi Liu,(unknown),Charity Atkins,Melissa Dumble,Jingsong Yang,Kelly K. Anderson,Ryan G. Kruger,Richard R. Gontarek,Kenneth R. Maksimchuk,Sapna Suravajjala,(unknown),J. Brad Shotwell,Joseph W. Wilson,Stanley D. Chamberlain,Sridhar K. Rabindran,Rakesh Kumar	86
4	Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase 2009 ·Clinical Cancer Research ·Peter Sabbatini,Jason L. Rowand,Arthur Groy,Susan Korenchuk,Qi Liu,Charity Atkins,Melissa Dumble,Jingsong Yang,Kelly K. Anderson,Brian J. Wilson,Kyle A. Emmitte,Sridhar K. Rabindran,Rakesh Kumar	62
5	Abstract #1740: Characterization of GSK1838705A, a small molecule inhibitor of the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase that delays growth of IGF-1R-dependent tumors and causes regression of ALK-dependent tumors in vivo 2009 ·Cancer Research ·Sridhar K. Rabindran,Peter Sabbatini,Susan Korenchuk,Arthur Groy,Jason L. Rowand,Qi Liu,(unknown),Charity Atkins,Melissa Dumble,Jingsong Yang,Kelly E. Fisher,Ryan G. Kruger,Kenneth R. Maksimchuk,Richard R. Gontarek,Sapna Suravajjala,(unknown),J. Brad Shotwell,Joseph W. Wilson,Stanley D. Chamberlain,Rakesh Kumar	2
6	Synthesis, SAR study and biological evaluation of novel pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as anti-proliferative agents 2008 ·Bioorganic & Medicinal Chemistry ·Yanong D. Wang,(unknown),Biqi Wu,S.A. Johnson,Dennis Powell,Miriam Miranda,John P. McGinnis,Carolyn Discafani,Sridhar K. Rabindran,Wendy H.Y. Cheng,Girija Krishnamurthy	34
7	Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel antiproliferative agents: Exploration of core and headpiece structure–activity relationships 2007 ·Bioorganic & Medicinal Chemistry Letters ·Dennis Powell,Ariamala Gopalsamy,Yanong D. Wang,Nan Zhang,Miriam Miranda,John P. McGinnis,Sridhar K. Rabindran	32
8	Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibbreakdown → 2005 ·Proceedings of the National Academy of Sciences ·Eunice L. Kwak,Raffaella Sordella,Daphne W. Bell,Nadia Godin-Heymann,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,David R. Driscoll,Panos Fidias,Thomas J. Lynch,Sridhar K. Rabindran,John P. McGinnis,Allan Wissner,Sreenath V. Sharma,Kurt J. Isselbacher,Jeffrey Settleman,Daniel A. Haber	774
9	Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity 2005 ·Journal of Medicinal Chemistry ·Hwei‐Ru Tsou,(unknown),William Hallett,Marvin F. Reich,M. Brawner Floyd,Bernard D. Johnson,Ronald S. Michalak,Ramaswamy Nilakantan,Carolyn Discafani,Jonathan Golas,Sridhar K. Rabindran,Ru Shen,Xiaoqing Shi,Yu‐Fen Wang,Janis Upeslacis,Allan Wissner	246
10	Parallel synthesis and biological evaluation of 5,6,7,8-tetrahydrobenzothieno[2,3-d]pyrimidin-4(3H)-one cytotoxic agents selective for p21-deficient cells 2005 ·Bioorganic & Medicinal Chemistry Letters ·Lee D. Jennings,Scott L. Kincaid,Yanong D. Wang,Girija Krishnamurthy,Carl F. Beyer,John P. McGinnis,Miriam Miranda,Carolyn Discafani,Sridhar K. Rabindran	70
11	Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression 2005 ·Breast Cancer Research and Treatment ·Mary Grillo,Matthew J. Bott,(unknown),John P. McGinnis,Miriam Miranda,(unknown),Edward Rosfjord,Sridhar K. Rabindran	73
12	Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel anti-proliferative agents: parallel synthesis for lead optimization of amide region 2005 ·Bioorganic & Medicinal Chemistry Letters ·Ariamala Gopalsamy,Hui Yang,John W. Ellingboe,Hwei‐Ru Tsou,Nan Zhang,(unknown),Dennis Powell,Miriam Miranda,John P. McGinnis,Sridhar K. Rabindran	56
13	4-Anilino-3-cyanobenzo[g]quinolines as Kinase Inhibitors 2002 ·Bioorganic & Medicinal Chemistry Letters ·Nan Zhang,Biqi Wu,Allan Wissner,Dennis Powell,Sridhar K. Rabindran,Constance Kohler,Frank Boschelli	13
14	A Novel Association between the Human Heat Shock Transcription Factor 1 (HSF1) and Prostate Adenocarcinoma 2000 ·American Journal Of Pathology ·Arthur T. Hoang,Jiapeng Huang,Nandini Rudra-Ganguly,Jianping Zheng,William C. Powell,Sridhar K. Rabindran,Carl Wu,Pradip Roy‐Burman	124
15	Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. 1998 ·PubMed ·Sridhar K. Rabindran,H He,Manu Smriti Singh,Eric Brown,(unknown),Tami Annable,Lee M. Greenberger	262
16	Displacement of sequence-specific transcription factors from mitotic chromatin 1995 ·Cell ·Marian A. Martínez‐Balbás,Anup Dey,Sridhar K. Rabindran,Keiko Ozato,Carl Wu	380
17	Interaction between Heat Shock Factor and hsp70 Is Insufficient To Suppress Induction of DNA-Binding Activity In Vivo 1994 ·Molecular and Cellular Biology ·Sridhar K. Rabindran,Jan Wiśniewski,(unknown),(unknown),Carl Wu	26
18	16 Structure and Regulation of Heat Shock Transcription Factor 1994 ·Cold Spring Harbor Monograph Archive ·Carl Wu,Joachim Clos,(unknown),Raymond I. Haroun,(unknown),Sridhar K. Rabindran,J. Timothy Westwood,Jan Wiśniewski,(unknown)	10
19	Characterization of Oligosaccharide Chains on Mouse Mammary Tumor Virus Envelope Proteins and the Implications for the Mechanism of Their Glucocorticoid Regulated Processing 1990 ·Molecular Endocrinology ·Lauren Snider,Janis L. Corey,Sridhar K. Rabindran,Michael R. Stallcup	11
20	Mouse Lymphoma Cell Variants with Genetically Dominant Alterations in the Maturation of Viral Glycoproteins 1987 ·Molecular Endocrinology ·Sridhar K. Rabindran,Michael R. Stallcup	6

About Sridhar K. Rabindran

Sridhar K. Rabindran is a scholar working on Aging, Oncology and Toxicology, having authored 45 papers that have together received 5.7k indexed citations. Recurring topics across this work include Heat shock proteins research (10 papers), Cancer-related Molecular Pathways (8 papers) and HER2/EGFR in Cancer Research (6 papers). The work is most often cited by research in Aging (175 citations), Oncology (2.5k citations) and Physical and Theoretical Chemistry (460 citations). Sridhar K. Rabindran has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Carl Wu, Joachim Clos, Lee M. Greenberger, Jan Wiśniewski, Allan Wissner, Gianfranco Giorgi, Chi Wu, John P. McGinnis, Raymond I. Haroun and Weidong Yang. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact